Stocks and Investing Stocks and Investing
Wed, July 24, 2019

Sumant Kulkarni Maintained (BIIB) at Hold with Increased Target to $285 on, Jul 24th, 2019


Published on 2024-10-26 14:54:04 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Hold with Increased Target from $275 to $285 on, Jul 24th, 2019.

Sumant has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $250 on, Friday, June 28th, 2019
  • Laura Chico of "Wedbush" Initiated at Hold and Held Target at $231 on, Thursday, May 23rd, 2019
  • Geoff Meacham of "Barclays" Maintained at Hold with Decreased Target to $245 on, Thursday, May 9th, 2019


This is the rating of the analyst that currently disagrees with Sumant


  • Evan Seigerman of "Credit Suisse" Initiated at Sell and Held Target at $198 on, Tuesday, May 21st, 2019
Contributing Sources